32 results
8-K
EX-99.1
ZLAB
Zai Lab Limited
20 Oct 21
ZL-1102, Zai Lab’s Internally Developed Novel Human
4:06pm
in patients with mild-to-moderate chronic plaque
psoriasis; consistent improvement was seen over time
First study to demonstrate penetration of protein … the safety, pharmacokinetics, and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP). ZL-1102
8-K
EX-99.1
ZLAB
Zai Lab Limited
6 Jan 21
Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
4:08pm
: myasthenia gravis (MG), a chronic disease that causes muscle weakness; pemphigus vulgaris (PV), a chronic disease characterized by severe blistering … of the skin; immune thrombocytopenia (ITP), a chronic bruising and bleeding disease; and chronic inflammatory demyelinating polyneuropathy (CIDP
8-K
EX-99.1
ZLAB
Zai Lab Limited
27 Feb 24
Zai Lab Announces Full-Year 2023
4:12pm
China submissions:
–Efgartigimod SC in chronic inflammatory demyelinating polyneuropathy (CIDP)
–Adagrasib in second-line+ NSCLC
–Tisotumab vedotin … in chronic plaque psoriasis (CPP)
Enroll patients in the global Phase 1 study for ZL-1310 (DLL3 ADC) in small cell lung cancer (SCLC)
1 Mainland China
8-K
ZLAB
Zai Lab Limited
20 Oct 21
ZL-1102, Zai Lab’s Internally Developed Novel Human
4:06pm
, pharmacokinetics, and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis. ZL-1102 is an investigational
8-K
EX-99.3
ZLAB
Zai Lab Limited
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm
(ITP), chronic inflammatory demyelinating polyneuropathy (CIDP) and pemphigus.
Continue to explore and advance additional indications in coordination … other anti-IL-17 products, ZL-1102 is being developed as a topical treatment for mild-to-moderate chronic plaque psoriasis (CPP).
Recent Product
8-K
EX-99.1
0fl65y 79ids2
8 May 24
Zai Lab Announces First Quarter 2024
4:09pm
8-K
EX-99.1
3453y955
1 Mar 22
Results of Operations and Financial Condition
4:17pm
8-K
EX-99.1
vaevmep
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
8-K
EX-99.1
ht7y0kqk
7 Nov 23
Zai Lab Announces Third Quarter 2023
4:10pm
8-K
EX-99.1
8j7tuyvzmdz
10 May 21
Zai Lab Reports First Quarter 2021 Financial Results
8:55am
8-K
EX-99.1
de8q5lz8ft
1 Mar 21
Zai Lab Announces Financial Results
7:01am
8-K
EX-99.1
9g2uz070tzy rji
9 Nov 22
Zai Lab Announces Third Quarter 2022
4:13pm
8-K
EX-99.1
dlpvmppj bgr0
30 Jun 23
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
4:18pm
6-K
EX-99.1
qkaag9tl
13 Aug 20
Current report (foreign)
7:30am
8-K
EX-99.1
zfnd1n
7 Aug 23
Zai Lab Announces Second Quarter 2023
4:07pm
8-K
EX-99.1
xnslclfg
9 May 23
Zai Lab Announces First Quarter 2023
4:03pm
8-K
EX-99.1
dyto3c6p5e6k1vn3p
9 Aug 21
Zai Lab Announces Second Quarter 2021
4:06pm
8-K
EX-99.1
husy9djjkqibgmn463c
9 Aug 22
Zai Lab Announces Second Quarter 2022
12:00am